cadonilimab
akesobio
['ak104', 'cadonilimab', 'akeso']
#akeso announces oral presentation featuring promising clinical data of #cadonilimab (#pd1 #ctla4 #bsabs #ak104) for the first-line treatment of r/m #cervicalcancer at #asco22 
Follow top-line development in the oncology commercial domain. Gain entry to KOL discussions, including both medical professionals and business leaders.